Regenxbio rises on early data from gene therapy for muscle disorder

Gene therapy developer Regenxbio's RGNX.O shares rise 4.5% to $8.15

Co reports interim early-stage data for its experimental gene therapy, RGX-202, for the treatment of Duchenne muscular dystrophy (DMD)

DMD causes skeletal and heart muscle weakness that quickly worsens with time

The interim data from two additional patients, including one aged 3 years, builds on the favorable safety and efficacy profile seen in ages 4 and older - RGNX

Co says there were no serious adverse events

Co plans to share further functional early-stage data in H1 2025

Including session gains, RGNX has fallen 63% in the past 12 months